Literature DB >> 11071087

Asn540Lys mutation in fibroblast growth factor receptor 3 and phenotype in hypochondroplasia.

G Grigelioniené1, O Eklöf, E Laurencikas, B Ollars, N T Hertel, J P Dumanski, L Hagenäs.   

Abstract

UNLABELLED: Hypochondroplasia is characterized by a disproportionate short stature with rhizomelic shortening of the limbs. Amino acid substitutions Asn540Lys, Asn540Thr and Ile538Val in the fibroblast growth factor receptor 3 (FGFR3) are considered to cause hypochondroplasia. In this study we examined the FGFR3 gene for the previously described hypochondroplasia mutations and the phenotype of 23 probands with clinically and radiologically diagnosed hypochondroplasia. For the phenotype comparison, the patients were divided into two groups: Group 1: hypochondroplasia with Asn540Lys substitution; Group 2: hypochondroplasia with no mutations identified so far. A three-generation family negative for the known hypochondroplasia mutations was examined with polymorphic markers flanking the FGFR1, FGFR2 and FGFR3 genes. Nine (39%) of 23 probands were found to be heterozygous for the Asn540Lys substitution. The individuals positive for the Asn540Lys substitution were significantly more disproportionate than the individuals without this mutation. In this respect, a genotype-phenotype correlation was found in our patients. However, some individuals belonging to the group without mutations identified so far showed similarly abnormal proportions. Genotyping/haplotyping in the three-generation family with hypochondroplasia showed that FGFR1, FGFR2 and FGFR3 genes were not linked to the hypochondroplasia phenotype in this family, thus further confirming the genetic heterogeneity of hypochondroplasia.
CONCLUSION: Individuals with hypochondroplasia heterozygous for the Asn540Lys substitution are significantly more disproportionate than individuals without this mutation. Our study further confirms the clinical and genetic heterogeneity of hypochondroplasia.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11071087     DOI: 10.1080/713794579

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


  5 in total

1.  A molecular brake in the kinase hinge region regulates the activity of receptor tyrosine kinases.

Authors:  Huaibin Chen; Jinghong Ma; Wanqing Li; Anna V Eliseenkova; Chongfeng Xu; Thomas A Neubert; W Todd Miller; Moosa Mohammadi
Journal:  Mol Cell       Date:  2007-09-07       Impact factor: 17.970

2.  Distinct missense mutations of the FGFR3 lys650 codon modulate receptor kinase activation and the severity of the skeletal dysplasia phenotype.

Authors:  G A Bellus; E B Spector; P W Speiser; C A Weaver; A T Garber; C R Bryke; J Israel; S S Rosengren; M K Webster; D J Donoghue; C A Francomano
Journal:  Am J Hum Genet       Date:  2000-10-27       Impact factor: 11.025

3.  Elucidation of a four-site allosteric network in fibroblast growth factor receptor tyrosine kinases.

Authors:  Huaibin Chen; William M Marsiglia; Min-Kyu Cho; Zhifeng Huang; Jingjing Deng; Steven P Blais; Weiming Gai; Shibani Bhattacharya; Thomas A Neubert; Nathaniel J Traaseth; Moosa Mohammadi
Journal:  Elife       Date:  2017-02-06       Impact factor: 8.140

4.  Evaluation of Efficacy of Long-term Growth Hormone Therapy in Patients with Hypochondroplasia

Authors:  Tuğba Çetin; Zeynep Şıklar; Pınar Kocaay; Merih Berberoğlu
Journal:  J Clin Res Pediatr Endocrinol       Date:  2018-05-09

5.  Successful birth with preimplantation genetic diagnosis using single-cell allele-specific PCR and sequencing in a woman with hypochondroplasia due to FGFR3 mutation (c.1620C>A, p.N540K).

Authors:  Kyung Eui Park; Sung Ah Kim; Moon Joo Kang; Hee Sun Kim; Sung Im Cho; Kyoung Won Yoo; So Yeon Kim; Hye Jun Lee; Sun Kyung Oh; Moon-Woo Seong; Seung-Yup Ku; Jong Kwan Jun; Sung Sup Park; Young Min Choi; Shin Yong Moon
Journal:  Clin Exp Reprod Med       Date:  2013-03-31
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.